The original study aimed to investigate a vasculo-regenerative program in pulmonary endothelium mediated by the PPARγ-p53 transcription factor complex and demonstrated the potential role of a novel p53-based therapeutic strategy for PAH [42]. The gene discussed is TP53; the disease is pulmonary arterial hypertension.